Provenienza dei contatti di primo grado di Lucy E Wallace
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.
47
| Operating Division | Investment Managers | 47 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Lucy E Wallace tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
INKEF Capital BV
INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor Private Equity Analyst Private Equity Investor | |
Indi Molecular, Inc.
Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Calypso Biotech SA
Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
University of St. Andrews | College/University | Undergraduate Degree Undergraduate Degree | |
University of Cambridge | College/University | Undergraduate Degree Graduate Degree | |
DNA Script SAS
DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Chairman Director/Board Member | |
University of Innsbruck | College/University | Graduate Degree | |
University of Zurich | College/University | Doctorate Degree | |
Delta Partners Ltd.
Delta Partners Ltd. Investment ManagersFinance Delta Partners Ltd (Delta Partners) is an independent venture capital firm founded in 1994 by Mr. Frank Kenny. The firm is headquartered in Ireland with an additional office in the United Kingdom. | Investment Managers | Private Equity Investor | |
Lundbeckfonden Emerge
Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor | |
Redalpine Venture Partners AG
Redalpine Venture Partners AG Investment ManagersFinance Redalpine Venture Parners AG (Redalpine) is an independent venture capital investment firm headquartered in Zurich, Switzerland. The firm was founded in 2006. | Investment Managers | Private Equity Analyst | |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Seventure Partners SA
Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris. | Investment Managers | Private Equity Analyst | |
NanoSyrinx Ltd
NanoSyrinx Ltd Miscellaneous Commercial ServicesCommercial Services NanoSyrinx Ltd is a discovery stage biotechnology company that is based in the UK. The British company is focused on developing protein nanosyringes as a new way to deliver protein and peptide biologic drugs intracellularly. The company uses synthetic biology approaches to achieve this goal. The company was founded by Joseph Healey, Alexia Hapeshi, and Nicholas Waterfield, with Joseph Healey serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Pictor Labs, Inc.
Pictor Labs, Inc. Information Technology ServicesTechnology Services Pictor Labs, Inc. engages in technology industry. The company is headquartered in Los Angeles, CA. | Information Technology Services | Director/Board Member | |
IIF Management Co. LLC
IIF Management Co. LLC Investment ManagersFinance IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California. | Investment Managers | Private Equity Investor | |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | Biotechnology | Director/Board Member | |
Sonde Health, Inc.
Sonde Health, Inc. Packaged SoftwareTechnology Services Sonde Health, Inc. develops voice-based technology platform to monitor and diagnose psychological and physical medical conditions. The company was founded by Michael C. Chen and James Harper in 2015 and is headquartered in Boston, MA. | Packaged Software | Director/Board Member | |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor | |
OBSEVA SA | Pharmaceuticals: Major | Director/Board Member | |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
University of Groningen | College/University | Doctorate Degree | |
Netherlands Vaccine Institute | Corporate Officer/Principal | ||
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Calypso Biotech BV
Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands. | Biotechnology | Director/Board Member | |
Amadeus Capital Partners Ltd.
Amadeus Capital Partners Ltd. Investment ManagersFinance Amadeus Capital Partners Ltd is an independent venture capital firm is founded by Anne Glover and Hermann Hauser in 1997. The firm is headquartered in London, UK. | Investment Managers | Private Equity Investor | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
ENGENE HOLDINGS INC. | Biotechnology | Director/Board Member | |
Van Lanschot Kempen NV (Broker)
Van Lanschot Kempen NV (Broker) Investment Banks/BrokersFinance Van Lanschot Kempen NV (Broker) (Van Lanschot Kempen-Broker) is the broker-dealer division of Van Lanschot Kempen NV (AMS: VLK), a financial institution headquartered in Amsterdam, Netherlands. The firm was founded in 1903 and formerly known as Kempen & Co. NV. Van Lanschot Kempen-Broker provides securities broking to institutional investors, companies, financial institutions, (semi) public institutions, foundations and high net-worth individual clients. | Investment Banks/Brokers | Sales & Marketing | |
Medisafe Project Ltd.
Medisafe Project Ltd. Hospital/Nursing ManagementHealth Services Medisafe Project Ltd. develops a cloud-synced mobile medication management system. Its platform helps the user manage and take medication on time. The company was founded by Omri Shor and Rotem Shor in 2012 and is headquartered in Matam, Israel. | Hospital/Nursing Management | Director/Board Member | |
Biolinq, Inc.
Biolinq, Inc. Electronic Production EquipmentElectronic Technology Biolinq, Inc. develops skin-applied electronic sensors that analyze body fluids to provide health information. The company was founded by Jared Tangney and Josh Windmiller in 2012 and is headquartered in San Diego, CA. | Electronic Production Equipment | Director/Board Member | |
Escp Business School | College/University | Graduate Degree | |
Scipio Bioscience SAS
Scipio Bioscience SAS Miscellaneous Commercial ServicesCommercial Services Scipio Bioscience SAS operates as a biotechnology company. It provides a novel sample preparation solution for single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics. The company was founded by Pierre Walrafen and Stuart Edelstein on August 2, 2017 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member | |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Analyst | |
High-Tech Gründerfonds Management GmbH
High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Investor | |
Skywell Capital Partners
Skywell Capital Partners Investment ManagersFinance Skywell Capital Partners (Skywell) is a venture capital firm founded in 2014. The firm is headquartered in Tel Aviv, Israel. | Investment Managers | Private Equity Investor | |
University of California, Los Angeles | College/University | Chief Tech/Sci/R&D Officer | |
BRERA HOLDINGS PLC | Movies/Entertainment | Director/Board Member | |
Atelier Mnemist SAS | Founder | ||
The Royaland Co. Ltd.
The Royaland Co. Ltd. Financial ConglomeratesFinance The Royaland Co. Ltd. engages in creating an online and offline immersive, fantasy-based royalty-themed experience called myRoyal.World, centered around a mobile-first massively multiplayer online role-playing game, or MMORPG, called TheRoyal.Land. It offers proprietary digital avatars and provide opportunities for players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features in-game content. The company was founded by Emanuele Filiberto di Savoia on October 18, 2022 and is headquartered in Hamilton, Bermuda. | Financial Conglomerates | Director/Board Member | |
The University of Queensland | College/University | Graduate Degree |
Statistiche
Distribuzione geografica
Svizzera | 11 |
Stati Uniti | 9 |
Paesi Bassi | 8 |
Francia | 7 |
Regno Unito | 5 |
Settori
Health Technology | 17 |
Finance | 16 |
Consumer Services | 10 |
Commercial Services | 5 |
Technology Services | 3 |
Posizioni
Director/Board Member | 99 |
Private Equity Analyst | 43 |
Private Equity Investor | 33 |
Corporate Officer/Principal | 13 |
Graduate Degree | 8 |
Contatti più connessi
Insiders | |
---|---|
Joey Mason | 31 |
Roel Bulthuis | 29 |
Hakan Goker | 18 |
Dave Rosenberg | 15 |
Jasper Bos | 15 |
Yoni Blau | 11 |
Andreas Jurgeit | 8 |
Alberto Libanori | 8 |
Arnaud Autret | 7 |
Edward Kliphuis | 7 |
Dougal Adamson | 6 |
Keno Gutierrez | 6 |
Pieter Jeroen Bakker | 5 |
Therese Maria Liechtenstein | 4 |
Benson Lei | 3 |
- Borsa valori
- Insiders
- Lucy E Wallace
- Connessioni Società